Moderna, Inc. (NASDAQ:MRNA) CEO Sells $5,484,400.00 in Stock

Moderna, Inc. (NASDAQ:MRNAGet Rating) CEO Stephane Bancel sold 40,000 shares of Moderna stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $137.11, for a total value of $5,484,400.00. Following the sale, the chief executive officer now directly owns 5,411,946 shares in the company, valued at approximately $742,031,916.06. The sale was disclosed in a document filed with the SEC, which is available at this link.

Stephane Bancel also recently made the following trade(s):

  • On Wednesday, September 7th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $133.68, for a total value of $5,347,200.00.
  • On Wednesday, August 24th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $142.21, for a total value of $5,688,400.00.
  • On Wednesday, August 17th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $159.03, for a total value of $6,361,200.00.
  • On Wednesday, August 10th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $172.29, for a total value of $6,891,600.00.
  • On Thursday, August 4th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $192.94, for a total value of $7,717,600.00.
  • On Thursday, July 28th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $156.73, for a total value of $6,269,200.00.
  • On Thursday, July 21st, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $168.11, for a total value of $6,724,400.00.
  • On Wednesday, July 13th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $172.69, for a total value of $6,907,600.00.
  • On Thursday, July 7th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $171.00, for a total value of $6,840,000.00.
  • On Thursday, June 30th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $143.21, for a total value of $5,728,400.00.

Moderna Stock Up 1.4 %

Moderna stock opened at $137.74 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.99 and a quick ratio of 1.71. Moderna, Inc. has a fifty-two week low of $115.61 and a fifty-two week high of $458.50. The company’s 50 day simple moving average is $156.09 and its 200 day simple moving average is $151.09. The firm has a market capitalization of $54.79 billion, a price-to-earnings ratio of 4.20, a PEG ratio of 0.79 and a beta of 1.69.

Moderna (NASDAQ:MRNAGet Rating) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported $5.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.73 by $0.51. Moderna had a net margin of 61.12% and a return on equity of 94.76%. The company had revenue of $4.73 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same period last year, the company earned $6.46 earnings per share. The firm’s revenue was up 8.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Moderna, Inc. will post 26.41 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Argus reduced their price objective on Moderna from $180.00 to $150.00 and set a “buy” rating on the stock in a research note on Wednesday. SVB Leerink boosted their price objective on Moderna from $70.00 to $77.00 and gave the stock an “underperform” rating in a research note on Monday, August 1st. Morgan Stanley reduced their price objective on Moderna from $199.00 to $197.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 4th. Finally, Deutsche Bank Aktiengesellschaft upgraded Moderna from a “hold” rating to a “buy” rating and boosted their target price for the stock from $155.00 to $165.00 in a research report on Wednesday, September 7th. One analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $211.08.

Hedge Funds Weigh In On Moderna

Institutional investors have recently added to or reduced their stakes in the company. Keybank National Association OH boosted its position in Moderna by 22.1% during the first quarter. Keybank National Association OH now owns 2,877 shares of the company’s stock worth $496,000 after purchasing an additional 521 shares during the period. Oliver Lagore Vanvalin Investment Group acquired a new stake in shares of Moderna in the first quarter valued at approximately $30,000. Fieldpoint Private Securities LLC raised its position in shares of Moderna by 103.8% in the first quarter. Fieldpoint Private Securities LLC now owns 214 shares of the company’s stock valued at $37,000 after buying an additional 109 shares in the last quarter. Metis Global Partners LLC raised its position in shares of Moderna by 79.5% in the first quarter. Metis Global Partners LLC now owns 5,530 shares of the company’s stock valued at $953,000 after buying an additional 2,450 shares in the last quarter. Finally, Ellis Investment Partners LLC raised its position in shares of Moderna by 112.5% in the first quarter. Ellis Investment Partners LLC now owns 425 shares of the company’s stock valued at $73,000 after buying an additional 225 shares in the last quarter. 60.76% of the stock is currently owned by institutional investors and hedge funds.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Featured Articles

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.